Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Sourcing from reputable suppliers who provide third-party testing certificates, maintain proper storage and handling, offer consistent product quality, and demonstrate transparency about their manufacturing processes helps mitigate these risks
Together, these observations suggest that BPC-157 functions as a modulator of interconnected signaling networks involving nitric oxide regulation, kinase mediated cytoskeletal signaling, and endothelial pathway activation in experimental biological systems
You might notice that the swelling around the injury site begins to dissipate faster than usual
The optimal time for AOD-9604 administration is in a completely fasted state, typically first thing in the morning upon waking after an overnight fast of 8-10 hours
The trial did not resume enrollment Preclinical cardiac evidence: Animal models of myocardial infarction demonstrated RGN-352 reduced scar volume, improved cardiac function, and increased survival, forming the basis for the clinical program (PMID: 25015963) RGN-259 (Thymosin Beta-4 Ophthalmic Solution for Dry Eye): ARISE-1 and ARISE-2 Phase 3 trials: Evaluated Thymosin Beta-4 eye drops for dry eye disease with mixed results some endpoints showed improvement in signs of dry eye, but the pre-specified co-primary endpoints were not met, though some secondary endpoints showed statistically significant improvements in certain signs of dry eye (PMID: 23050815) These ophthalmic trials represent the most advanced clinical testing of any Thymosin Beta-4 formulation Independent Pilot Study (China, 2016): A small pilot study randomized 10 STEMI (heart attack) patients into two groups: 5 receiving Thymosin Beta-4-pretreated endothelial progenitor cells (EPCs) and 5 receiving untreated EPCs After 6 months, the Thymosin Beta-4-pretreated group showed trends toward improved cardiac function markers including ejection fraction and exercise capacity, though the very small sample size (n=5 per group) means these results should be considered hypothesis-generating only, not evidence of efficacy (PMID: 27288307) No severe complications were reported in either group during follow-up Important: This study used Thymosin Beta-4 as a cell pretreatment agent ex vivo (EPCs exposed to TB4 before transplantation), not as a directly administered drug
At Perfect B in Doral, FL, we actually prescribe BPC-157 as part of our peptide therapy program
